Reflow Medical Extends Global Presence with Launch of New European Subsidiary
Reflow Medical, Inc., a pioneer in developing advanced medical devices for complex cardiovascular conditions, has revealed the establishment of its European subsidiary in Landsberg am Lech, Germany. This strategic move bolsters the company’s global footprint and improves its capacity to serve markets beyond the United States.
Reflow Medical, a leader in the development of innovative medical devices for complex cardiovascular diseases, has made a significant step forward in its global expansion by opening its European subsidiary, Reflow Medical Europe GmbH, in Landsberg am Lech, Germany. This strategic move is expected to bolster the company’s ability to meet the growing demand for advanced cardiovascular technologies in international markets while reinforcing its commitment to improving patient outcomes worldwide.
Reflow Medical Europe GmbH is headed by Senior Vice President and General Manager, Knut Sauerteig, whose leadership will guide the company in establishing a direct sales network and forming key distribution partnerships across multiple regions. Under Sauerteig’s guidance, the subsidiary aims to increase accessibility to Reflow’s advanced product portfolio, which includes both coronary and peripheral catheters, enabling healthcare providers across Europe and beyond to offer cutting-edge treatments to patients with complex cardiovascular conditions.
“Expanding into markets outside the United States marks a significant milestone for our company,” said Isa Rizk, Co-Founder and CEO of Reflow Medical. “By establishing a strong European presence, we can better address the needs of international markets through direct sales channels and strategic distribution collaborations. Our goal is to deliver breakthrough technologies that support physicians in their mission to improve patient outcomes, not just in the U.S., but across the globe.”
The new European subsidiary is part of Reflow’s broader strategy to enhance its international footprint. The company believes that establishing a local presence in Europe will help streamline the distribution process, improving delivery times and service reliability for healthcare providers. John Fulkerson, Co-Founder and COO of Reflow Medical, elaborated on the operational advantages of this expansion: “Having a European base allows us to reduce delivery times significantly and enhance the reliability of our service. These operational efficiencies are vital to maintaining the high standards of quality and care that the medical device industry demands.”
With a focus on Europe, the Middle East, Africa, Latin America, and the Asia-Pacific region, Reflow Medical’s global expansion is aimed at delivering more timely and effective solutions to healthcare providers in diverse regions. Sauerteig emphasized the company’s long-term vision: “We are committed to driving growth across multiple international markets. In the coming years, we will continue to build direct sales teams and strengthen distribution partnerships to ensure that we are effectively meeting the needs of healthcare professionals and patients in these areas.”
This expansion into Europe and other international markets is a reflection of Reflow Medical’s dedication to advancing cardiovascular care globally. By extending its reach, the company is positioning itself to play an even more significant role in improving the lives of patients worldwide through innovative medical devices. Reflow Medical’s robust portfolio of products, which includes unique coronary and peripheral catheters, is central to the company’s mission of addressing complex cardiovascular diseases.
Reflow’s flagship product, the CoraCatheters™ line, is designed to navigate challenging coronary lesions and is currently available only in the U.S. In addition, Reflow’s Wingman™ CTO Crossing Catheter, the Spex® and Spex® LP Shapeable Support Microcatheters, and the Spur® Peripheral Retrievable Scaffold System are vital tools for treating complex peripheral vascular conditions. The Spur device, in particular, has earned the CE Mark for treating restenotic lesions in below-the-knee arteries when used alongside a commercially available drug-coated balloon. In the U.S., the Spur remains an investigational device, but its CE Mark approval enables Reflow Medical to bring it to patients in Europe and other regions.
Reflow Medical’s expansion into the European market and beyond is not just a milestone for the company, but also for the global medical community. The company’s commitment to developing innovative technologies to address unmet clinical needs is evident in its diverse product offerings, which aim to improve patient outcomes and provide physicians with the tools they need to manage complex cardiovascular diseases more effectively.
As Reflow Medical continues to grow its international presence, the company is poised to make a lasting impact on cardiovascular care worldwide. With a focus on innovation, quality, and patient-centered solutions, Reflow Medical is well-positioned to meet the demands of healthcare providers and patients across the globe.
About Reflow Medical, Inc.
Reflow Medical is a global company focused on developing innovative medical technologies in collaboration with leading physicians to address the unmet clinical needs in complex cardiovascular disease treatment. The company’s product portfolio includes the CoraCatheters™ line of coronary microcatheters (currently available in the U.S.), as well as unique peripheral catheters like the Wingman™ CTO Crossing Catheter, Spex® and Spex® LP Shapeable Support Microcatheters, and the Spur® Peripheral Retrievable Scaffold System. The Spur device has received the CE Mark for the treatment of restenotic lesions in below-the-knee arteries when used in combination with a commercially available drug-coated balloon. Reflow Medical is headquartered in San Clemente, California.
